As­traZeneca spins out a bis­pe­cif­ic an­ti­body in­to a new can­cer biotech with part­ner AbPro

As­traZeneca’s big sub­sidiary Med­Im­mune and syn­thet­ic bi­ol­o­gy play­er AbPro are join­ing forces on a spin-out com­pa­ny which will un­der­take the de­vel­op­ment of a pre­clin­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER